THE EFFECT OF METFORMIN ON B12, LDL, AND LIVER ENZYMES LEVEL IN DIABETIC PATIENTS IN IRAQ
Keywords:
Type 2 diabetes mellitus, Metformin monotherapy, Hyperglycemia, B12 levels, LDL cholesterolAbstract
Background: Diabetes mellitus is a heterogeneous group of disorders characterized by hyperglycemia due to an absolute or relative deficit in insulin production or action. The chronic hyperglycemia of diabetes mellitus is associated with end organ damage, dysfunction, and failure, including the retina, kidney, nervous system, heart, and blood vessels. Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes.
Method: In private laboratories located in Baghdad, Iraq, a prospective study was carried out between September 2023 and January 2024. Men and women under the age of 70 who had recently been diagnosed with type 2 diabetes mellitus and who were on metformin monotherapy and gave their informed agreement to participate in the study comprised the study population.
Results: The study recruited 50 patients with type 2 diabetes mellitus; patients were receiving metformin as their anti-hyperglycemic therapy. The mean age of the patients was 57±9, 30.8% were illiterated, 94.2% were married, 78.8% were non-smokers, and 53.8% were hypertensive. There was a significant difference in B12, LDL, AST, and ALT level after three months of treatment, P value (0.0001).
Conclusion: There was a significant difference in B12, LDL, AST, and ALT level after three months of treatment with metformin.
References
1. World Health Organization (WHO). Global Report on Diabetes; WHO: Geneva, Switzerland, 2017; Available online: http://www.who.int/diabetes/global-report/en/ (accessed on 22 September 2018).
2. Mathers, C.D.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3, e442. [Google Scholar] [CrossRef] [Green Version]
3. A. Zaboon Al-Majidi Z, Lami FH, Hakimi S. Proportion and Potential Risk Factors of Poor Glycemic Control among Patients with Type 2 Diabetes Mellitus: Experience of a Tertiary Center in Baghdad, Iraq, 2020. J Fac Med Baghdad [Internet]. 2024 Jul. 1 [cited 2024 Jul. 12];66(2):209-15.
4. S. Abdel Aziz Z, S, Dawood N, H. Al-khalisy M. Evaluation of the effect of type II diabetes mellitus on Bone Mineral Density of Upper and Lower Limbs by Dual-Energy X-Ray Absorptiometry. J Fac Med Baghdad [Internet]. 2023 Apr. 27 [cited 2024 Jul. 12];65(1):27-33.
5. Alzubaidi MA, jawad AA. Microalbuminuria in children and adolescent with type 1 Diabetes mellitus attending the diabetic center of children welfare teaching hospital. J Fac Med Baghdad [Internet]. 2014 Jan. 2 [cited 2024 Jul. 12];55(4):284-9.
6. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, et al.Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care, 38 (1) (2015), pp. 140-149.
7. Obeid R, Heil SG, Verhoeven MMA, van den Heuvel EGHM, de Groot LCPGM, Eussen SJPM. Vitamin B12 Intake From Animal Foods, Biomarkers, and Health Aspects. Front Nutr. 2019;6:93.
8. Ali, A., Unnikannan, H., Shafarin, J. et al. Metformin enhances LDL-cholesterol uptake by suppressing the expression of the pro-protein convertase subtilisin/kexin type 9 (PCSK9) in liver cells. Endocrine 76, 543–557 (2022). https://doi.org/10.1007/s12020-022-03022-x
9. Jalali M, Rahimlou M, Mahmoodi M, Moosavian SP, Symonds ME, Jalali R, Zare M, Imanieh MH, Stasi C. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacological Research. 2020 Sep 1;159:104799.
10. Gordis Epidemiology. Celentano DD & Armstrong C, 6th Edition ISBN: 978-0-323-55229-5; 2019 by Elsevier, Inc. PP: 179-215.
11. Biostatistics: A Foundation for Analysis in the Health Sciences. Wayne W Daniel & Chad L Cross; 11th ed.. John Wiley & Sons Inc, USA, 2019. PP: 600-670.
12. Introduction to the Practice of Statistics. Moore DS, McCabe GP & Craig BA. 9th edition, extended version. Purdue University. WH Freeman and Company, New York, 2009. PP: 900-1004.
13. Basic & Clinical Biostatistics. B Dawson & RG Trapp. Mc Graw Hill. 4th edition. 2004. PP: 24-162.
14. Fereshte JT, Soghra N: The effect of education based on health belief model on preventive behaviors of urinary tract infections in women. [Javaheri Tehrani F, Nikpour S, Haji Kazemi EA, Sanaie N, Shariat Panahi ShA. The Effect of Education Based on Health Belief Model on Health Beliefs of Women with Urinary Tract Infection. IJCBNM. 2014;2(1):2-11
15. Innovative Strategies for Remotely Sampling Hard-to-Reach Populations: Assessing Phone Versus Internet Respondent-Driven Sampling Approaches Among Venezuelan Refugees and Migrants in Colombia. Phuong N Pham, Lisa G Johnston, Katrina Keegan, Carol Wei, Patrick Vinck. American Journal of Epidemiology, Volume 192, Issue 10, October 2023, Pages 1613–1623, https://doi.org/10.1093/aje/kwad116
16. Kakarlapudi Y, Kondabolu SK, Tehseen Z, Khemani V, J SK, Nousherwani MD, Saleem F, Abdelhameed AN. Effect of Metformin on Vitamin B12 Deficiency in Patients With Type 2 Diabetes Mellitus and Factors Associated With It: A Meta-Analysis. Cureus. 2022 Dec 7;14(12):e32277.
17. Hurley-Kim K, Vu CH, Dao NM, Tran LC, McBane S, Lee J, Sepassi A. Effect of Metformin Use on Vitamin B12 Deficiency Over Time (EMBER): A Real-World Evidence Database Study. Endocr Pract. 2023 Nov;29(11):862-867. doi: 10.1016/j.eprac.2023.06.013. Epub 2023 Aug 21. Erratum in: Endocr Pract. 2024 Jan;30(1):86-87.
18. Kheniser KG, Kashyap SR, Kasumov T. A systematic review: the appraisal of the effects of metformin on lipoprotein modification and function. Obesity Science & Practice. 2019 Feb;5(1):36-45.
19. Rains SG, Wilson GA, Richmond W, Elkeles RS. The reduction of low density lipoprotein cholesterol by metformin is maintained with long-term therapy. Journal of the Royal Society of Medicine. 1989 Feb;82(2):93-4.
20. Rains SG, Wilson GA, Richmond W, Elkeles RS. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes. Diabetic medicine. 1988 Oct;5(7):653-8.
21. Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic Fatty liver disease: a randomized controlled pilot study. Hepat Mon. 2012 Aug;12(8):e6099.
22. Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC, Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity. 2010 Sep;18(9):1762-7.
23. Li Y, Liu L, Wang B, Wang JU, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta analysis. Biomedical reports. 2013 Jan 1;1(1):57-64.
24. Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic Fatty liver disease: a randomized double blinded clinical trial. Hepat Mon. 2013 May 21;13(5):e9270.
